Clinical trials: Cisplatin
Ovarian Neoplasms
Efficacy and Safety of Subsequent Cisplatin and Docetaxel in Ovarian Cancer
The purpose of this study is to assess the efficacy and the safety of the treatment.
- Trial name
- Tax-Over (NCT00772863)
- Testing
- docetaxel and cisplatin
- Where
- Turkey (Türkiye)
- Volunteers
- 37 people
- Sponsor
- Sanofi
Carcinoma, Non-Small-Cell Lung
Adjuvant Cisplatin With Either Genomic-Guided Vinorelbine or Pemetrexed for Early Stage Non-Small-Cell Lung Cancer
This study assigned subjects to either cisplatin/vinorelbine or cisplatin/pemetrexed chemotherapy using a genomic based expression profile to determine chemotherapy sensitivity in completely resected early stage non-squamous…
- Trial name
- TOP0703 (NCT00545948)
- Testing
- Vinorelbine followed by Cisplatin, Pemetrexed followed by Cisplatin
- Where
- 13 sites in United States
- Volunteers
- 31 people
- Sponsor
- Duke University
Lung Cancer
Cisplatin/Etoposide and Concurrent Radiotherapy With or Without Celecoxib in Patients With Unresectable Locally Advanced Non-small Cell Lung Cancer (NSCLC)
Concurrent chemoradiation (ChRT) is a standard care for unresectable stage III non-small cell lung cancer (NSCLC) patients with good performance status, and cisplatin/etoposide (EP) regimen is one of the most commonly used…
- Trial name
- NCT01503385
- Testing
- Celecoxib
- Where
- 2 sites in China
- Volunteers
- 100 people
- Sponsor
- Chinese Academy of Medical Sciences
Toxicity, Non-small Cell Lung Cancer
Study of Gefitinib Compared With Pemetrexed/Cisplatin in Advanced Non-Small Cell Lung Cancer Patients
The purpose of this study is to examine the efficacy and safety of gefitinib combinated with Pemetrexed/Cisplatin in advanced non-small cell lung cancer (NSCLC).
- Trial name
- NCT01192243
- Testing
- Gefitinib, Pemetrexed, Cisplatin or carboplatin
- Where
- China
- Volunteers
- 68 people
- Sponsor
- Fudan University
DDP, Head and Neck Cancer
Efficacy of Trans-tympanic Injections of a Sodium Thiosulfate Gel to Prevent Cisplatin-induced Ototoxicity
This study evaluates whether a gel containing sodium thiosulfate deposited via a trans-tympanic injection on the round window of the middle ear could reduce the ototoxicity caused by the drug Cisplatin among patients with head…
- Conditions
- DDP, Head and Neck Cancer, Adverse Effect
- Trial name
- STS001 (NCT02281006)
- Testing
- Trans-tympanic injection of a sodium thiosulfate gel
- Where
- Canada
- Volunteers
- 13 people
- Sponsor
- CHU de Quebec-Universite Laval
Lung Cancer
Combination Chemotherapy in Treating Patients With Extensive Stage Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003606
- Testing
- cisplatin, cyclophosphamide, epirubicin hydrochloride
- Where
- France
- Volunteers
- 216 people
- Sponsor
- UNICANCER
Stomach Neoplasms
Cisplatin and S-1 With or Without Nimotuzumab in Untreated Advanced Gastric Adenocarcinoma
In this open-label, single-center, small sample size, randomised, parallel-group, controlled study, the investigators aim to assess efficacy and safety of addition of nimotuzumab to CS chemotherapy in patients with previously…
- Trial name
- NCT02370849
- Testing
- nimotuzumab, cisplatin, S-1
- Where
- China
- Volunteers
- 2 people
- Sponsor
- Chinese Academy of Medical Sciences
Bladder Cancer, Ureter Cancer
Four Cycles Versus Six Cycles of Cisplatin-based Chemotherapy in Metastatic Urothelial Carcinoma
The objective is to show non-inferiority of overall survival between four cycles and six cycles of first-line cisplatin based chemotherapy to determine the optimal duration of chemotherapy in patients with advanced urothelial…
- Conditions
- Bladder Cancer, Ureter Cancer, Urethral Cancer, Transitional Cell Carcinoma
- Trial name
- FOCUS (NCT03296306)
- Testing
- Treatment duration of cisplatin based chemotherapy
- Where
- 19 sites in South Korea
- Volunteers
- 330 people
- Sponsor
- Asan Medical Center
Esophageal Squamous Cell Carcinoma
Neoadjuvant Chemotherapy With Nab-paclitaxel Plus Cisplatin and Capecitabine for Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma
Surgical resection is currently the major treatment for esophageal carcinoma while disease progression still occurred in most cases within 3 years.
- Trial name
- NCT04390958
- Testing
- nab-paclitaxel, Cisplatin, Capecitabine
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Chinese Academy of Medical Sciences
Cisplatin Nephrotoxicity, Nephrotoxicity
Alpha-Lipoic Acid in Mitigating Cisplatin-Induced Nephrotoxicity
To assess the nephroprotective efficacy of Alpha-Lipoic Acid in preventing cisplatin-induced nephrotoxicity in oncology patients by monitoring renal function changes
- Trial name
- NCT07564479
- Testing
- Alpha-Lipoic Acid (ALA)
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Minia University
Ovarian Cancer, Epithelial Ovarian Cancer
Heated Intraperitoneal Chemotherapy in Primary Ovarian Cancer Patients
This study will evaluate the use of Heated Intraperitoneal Chemotherapy (HIPEC) for primary treatment of ovarian cancer at the time of surgical debulking, to assess if intravenous (IV) chemotherapy can be started within 42 days…
- Conditions
- Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer
- Trial name
- NCT03321188
- Testing
- HIPEC, Carboplatin, Paclitaxel
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Andrea Jewell
Lung Cancer, Non Small Cell Lung Cancer
Apatinib Combine With Platinum-Based Doublet Chemotherapy for First-line Treatment of Advanced NSCLC
The purpose of this study is to evaluate the safety and clinical activity of Apatinib in combination with AP(Pemetrexed/Carboplatin) or AC(Pemetrexed/Carboplatin) as first-line chemotherapy in subjects with advanced EGFR wild…
- Conditions
- Lung Cancer, Non Small Cell Lung Cancer, Combination Chemotherapy, Apatinib
- Trial name
- NCT03201146
- Testing
- Apatinib, AP or AC, Apatinib 250mg
- Where
- China
- Volunteers
- 48 people
- Sponsor
- West China Hospital
Nasopharyngeal Carcinoma
Study to Evaluate Induction Chemotherapy Using Docetaxel, Cisplatin and Fluorouracil in Concurrence With Intensity-modulated Radiotherapy for Local Recurrent Nasopharyngeal Carcinoma (NPC)
Study Objective: Primary 1. To evaluate the complete response (CR) rate with induction chemotherapy using Docetaxel, Cisplatin and Fluorouracil(TPF) followed by Docetaxel plus Cetuximab (TC) in concurrence with…
- Trial name
- NCT01326559
- Testing
- Docetaxel, Cisplatin, 5-FU and Cetuximab
- Where
- 4 sites in China
- Volunteers
- 33 people
- Sponsor
- Hong Kong Nasopharyngeal Cancer Study Group Limited
Head and Neck Cancer
Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants (XRAY VISION)
The purpose of this study is to demonstrate the superior efficacy of Xevinapant (Debio 1143) versus placebo when added to radiotherapy in the treatment of high-risk participants with resected locally advanced squamous cell…
- Trial name
- NCT05386550
- Testing
- Xevinapant, IMRT
- Where
- 206 sites in United States, Argentina and 24 more
- Volunteers
- 166 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Cervical Carcinoma
Intensity Modulated Radiation Therapy With Cisplatin and Gemcitabine to Treat Locally Advanced Cervical Carcinoma
The primary objective of the study is to identify the highest dose of gemcitabine that can be given safely with cisplatin and pelvic intensity modulated radiation therapy (IMRT) in women with locally advanced cervical cancer.
- Trial name
- NCT01554410
- Testing
- Intensity Modulated Radiation Therapy (IMRT), Cisplatin, Gemcitabine
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- University of California, San Diego
Lung Cancer, Small Cell
Topotecan Plus Cisplatin Versus Etoposide Plus Cisplatin In 1st Line Extensive Disease Small Cell Lung Cancer
Evaluation of intravenous Topotecan + Cisplatin as a potential new standard of care in 1st line Small Cell Lung Cancer
- Trial name
- NCT00320359
- Testing
- Intravenous topotecan/cisplatin, Intravenous etoposide/cisplatin
- Where
- 79 sites in Austria, Germany
- Volunteers
- 700 people
- Sponsor
- GlaxoSmithKline
Esophageal Cancer Stage IIB, Esophageal Cancer Stage III
Paclitaxel, Cisplatin,5-FU vs. Radiotherapy Plus Paclitaxel, Cisplatin as Preoperative Therapy for Locally Advanced ESC
This is a Phase III clinical trail which Comparing Paclitaxel, Cisplatin Plus 5-FU (TCF) Versus Radiotherapy with Paclitaxel Plus Cisplatin (TC-RT) as Preoperative Therapy for Locally Advanced Esophageal Squamous Cancer.
- Trial name
- NCT03366883
- Testing
- Paclitaxel, Cisplatin Plus 5-FU (TCF), radiochemotherapy
- Where
- China
- Volunteers
- 420 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Metastatic Biliary Cancer
Trial of S-1 Plus Cisplatin (SP) Versus Gemcitabine Plus Cisplatin (GP) in Advanced Biliary Tract Adenocarcinoma
To select a better agent between S-1 or gemcitabine in combination with cisplatin for the conventional chemotherapy platform for future development in advanced Biliary Tract Adenocarcinoma (BTA), the investigators conduct a…
- Trial name
- NCT01375972
- Testing
- S-1 plus cisplatin, Gemcitabine plus Cisplatin
- Where
- South Korea
- Volunteers
- 92 people
- Sponsor
- Asan Medical Center
Esophageal Cancer
Radiation Therapy + Combination Chemotherapy as 1st-Line Therapy for Patients With Inoperable Esophageal Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as oxaliplatin, fluorouracil, leucovorin, and cisplatin, work in different ways to stop the growth of tumor cells, either…
- Trial name
- NCT00861094
- Testing
- cisplatin, 5-FU, oxaliplatin
- Where
- 28 sites in France
- Volunteers
- 266 people
- Sponsor
- UNICANCER
Squamous Cell Carcinoma of the Head and Neck
A Trial to Determine the Safety and Anti-tumor Activity Profile of the Combination of Cetuximab and Concomitant Cisplatin Plus 5-Fluorouracil (5-FU) in Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma in Head and Neck
The primary objective of this trial is to assess the antitumor activity and safety profile of cetuximab when given in combination with cisplatin + 5-Fluorouracil (5-FU) for the first-line treatment of recurrent and/or metastatic…
- Trial name
- CHANGE (NCT01177956)
- Testing
- Cetuximab, Cisplatin, 5-Fluorouracil
- Where
- 14 sites in China, South Korea
- Volunteers
- 73 people
- Sponsor
- Merck KGaA, Darmstadt, Germany